
Episode 21: Alan Ho live (post hoc) from the Multidisciplinary Head and Neck Cancers Symposium
31.5.2026
0:00
39:56
Alan Ho, Medical oncologist at MSKCC talks us through his work around Ozuriftamab Vedotin (Oz-V) and other ADC approaches. Ben criticises Will's combination approaches.
Weitere Episoden von „Deep Margin“



Verpasse keine Episode von “Deep Margin” und abonniere ihn in der kostenlosen GetPodcast App.








